Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Estramustine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.76 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.65 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 2/20 | 0.89 |
| ▸ | BLM | P54132 | 2/20 | 0.89 |
| ▸ | ESR1 | P03372 | 6/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.76 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.76 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.76 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | ATM | Q13315 | 2/20 | 0.65 |
| ▸ | PGR | P06401 | 2/20 | 0.65 |
| ▸ | AR | P10275 | 2/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estramustine SCHEMBL2534637 | 0.99 | RECQL (0.87) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL7552087 | 0.98 | RECQL (0.89) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL19197890 | 0.98 | RECQL (0.92) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL17350515 | 0.98 | RECQL (0.90) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL9509552 | 0.97 | RECQL (0.89) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL8342744 | 0.96 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL22129748 | 0.96 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL3625800 | 0.96 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL36761 | 0.96 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL15710412 | 0.95 | RECQL (0.92) | RECQLBLMESR1ADORA3INPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18986 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100969-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SARCOPENIA | 아주대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| EP-4735116-A2 | ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4694914-A1 | INHIBITION OF: STROMA/CANCER CELL CROSS-TALK &/OR STROMA GENERATED RESISTANCE TO TREATMENT | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | claimed |
| EP-4694915-A1 | TREATMENT OF HAEMATOLOGICAL CANCER | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | claimed |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2026-02-05 | — | — | US | claimed |
| US-12527836-B2 | Gla domains as targeting agents | GLAdiator Biosciences, Inc. (US) | 2026-01-20 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| WO-1997044336-A9 | CONJUGATES OF CIS-DOCOSAHEXAENOIC ACID AND PACLITAXEL | — | 1998-04-16 | — | — | WO | claimed |
| WO-1997044026-A1 | COMPOSITIONS COMPRISING CONJUGATES OF CIS-DOCOSAHEXAENOIC ACID AND TAXOTERE | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | claimed |
| WO-1997044336-A1 | CONJUGATES OF CIS-DOCOSAHEXAENOIC ACID AND PACLITAXEL | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | claimed |
| WO-1997042964-A1 | METHOD AND PRODUCT FOR PROMOTING HAIR GROWTH AND TREATING SKIN CONDITIONS | UNIVERSAL BIOLOG ENTERPRISES I (US) | 1997-11-20 | — | — | WO | claimed |
| EP-0794784-A1 | COMBINATION CHEMOTHERAPY OF SURAMIN AND A VINCA-ALKALOID OR ESTRAMUSTINE | WARNER-LAMBERT COMPANY (US) | 1997-09-17 | — | — | EP | claimed |
| EP-0769938-A1 | A NOVEL DRUG DELIVERY SYSTEM | THERAPICON SRL (IT) | 1997-05-02 | — | — | EP | claimed |
| WO-1996019226-A1 | COMBINATION CHEMOTHERAPY OF SURAMIN AND A VINCA-ALKALOID OR ESTRAMUSTINE | WARNER-LAMBERT COMPANY (US) | 1996-06-27 | — | — | WO | claimed |
| WO-1996001612-A1 | A NOVEL DRUG DELIVERY SYSTEM | THERAPICON S.R.L. (IT) | 1996-01-25 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| US-4115414-A | ESTRAMUSTINE PHOSPHATE ALCOHOL COMPLEXES, THEIR PREPARATION, AND THEIR USE AS INTERMEDIATES IN PURIFICATION OF SAID COMPOUND AND SALTS THEREOF | AKTIEBOLAGET LEO (SE) | 1978-09-19 | — | — | US | claimed |